Ment in the aspirin group. Fecal PI3K occult blood were H Maturie, gastrointestinal bleeding, and rhinorrhagia h Ufigsten types of extracranial bleeding.15 the results of this study confirm to a tendency for better efficacy of cilostazol compared with aspirin and improved security, represented by the statistically significant reduction of bleeding in the cilostazol group 0.15 The finding that h hemorrhagic stroke less hours was frequently with cilostazol is, given the outstanding hours here incidence of cerebral hemorrhages in patients of Asian origin compared to other ethnic groups.26, 27 However, based on the assumption CASISP generate test results, further analysis in a big en-3-phase study was ensured by weight that the trend to better assess effectiveness of aspirin for secondary cilostazol rpr Convention of stroke. Stroke Prevention Study 2 CILOSTAZOL The LSP-2 study was designed to meet the non-inferiority of cilostazol compared with To establish hnlichen tests aspirin.11 exclusively CSPS CSPS-2 study Lich in Japan was conducted at 278 sites between December 2003 and December 2008. Patients between the ages of 20 and 79 years who had prior to the stroke in 6.5 months without signs of cardiogenic embolism were randomized to cilostazol 100 mg orally two blind twice t Or 81 possible get to mg aspirin orally once t Possible for 1 5 years. Patients were excluded if they are connected with cardioemboli against-indications to aspirin or cilostazol, congestive heart failure, ulcer, kidney failure, liver disease, heart disease, or revascularization was made available. Before entering the study, 83% of patients received either cilostazol or aspirin, although affecting the concomitant use of thienopyridines or other drugs or platelet function H Hemostasis was banned. The prime Re endpoint was first recurrence of cases Schlaganf. Secondary Re endpoints included Todesf Lle any cause ICH, kardiovaskul Re bleeding events and a station Re treatment. Baseline characteristics of the two groups were comparable in all, au It in percentages COLUMNS significantly h Ago in patients receiving aspirin lowers the arm lipids and blood pressure medications. Blood pressure, but were also checked There in the two groups may need during the entire study period. A Gro Some of the patients had changed Rankin scores of 0 2 GE, W While 46% of patients had a score of 1 Similar proportions of patients had lakun subtypes Re atherothrombotic infarction before and strokes.11 data Antithrombotic Trialists Collaborative meta-analysis of antiplatelet therapy in patients with cerebral infarction and the results of the proposed test OPCS-risk ratio ratios Of 0.6 for aspirin and cilostazol compared with placebo.28 As a result, a hazard ratio of 1.33 for the AMN-107 given Non-inferiority of cilostazol was before the LSP 2 trial.11 The significance level for superiority trials set was set to 0.0471 set. After a mean treatment duration of 2.4 years, treatment with cilostazol with significant reductions in the primary Ren endpoint stroke was connected, because there were 82 shots in the cilostazol group and 119 strokes in the aspirin group. The p-value was below the adjusted level of significance for superiority trials, therefore, a final.